Clinical Trials Logo

Filter by:
NCT ID: NCT06304961 Active, not recruiting - Clinical trials for Healthy Participants

A Study to Investigate Relative Bioavailability of Two Different Dosage Forms for Tozorakimab Via Subcutaneous Administration in Healthy Volunteers

Start date: April 8, 2024
Phase: Phase 1
Study type: Interventional

The study will assess the relative bioavailability between two dosage forms of tozorakimab (test dosage form and reference dosage form) and to assess the pharmacokinetic (PK) profiles of both dosage forms.

NCT ID: NCT06266624 Active, not recruiting - HHT Clinical Trials

Tourniquet-Test in HHT

Start date: September 25, 2020
Phase: N/A
Study type: Interventional

The Tourniquet test is used as a diagnostic procedure for thrombocytopathies and vascular diseases. Currently, there is no evidence whether this test is also positive in hereditary haemorrhagic telangiectasia (HHT), a vasculopathy. The aim of this study was to investigate whether this non-invasive test could also be used as an additional diagnostic criterion in patients with HHT.

NCT ID: NCT06247683 Active, not recruiting - Cataract Senile Clinical Trials

Study to Confirm Safety and Performance of a New Multifocal IOL

Start date: March 13, 2023
Phase: N/A
Study type: Interventional

Prospective, non-comparative, multicenter study on medical device with 12 months follow-up.

NCT ID: NCT06221930 Active, not recruiting - Clinical trials for Adult Attention Deficit Hyperactivity Disorder

Researching the Effectiveness of Attexis, a Digital Health Application for Adults With Attention Deficit Hyperactivity Disorder

READ-ADHD
Start date: March 4, 2024
Phase: N/A
Study type: Interventional

In this randomized controlled clinical trial, 326 patients with ADHD will be investigated regarding the effectiveness of a digital therapeutic for improved ADHD symptomatology, the unguided online intervention attexis. Inclusion criteria are: male, female or non-binary, age 18-65, diagnosis of ADHD, elevated levels of ADHD symptoms (score of ≥17 either on the inattention subscale or on the impulsivity/hyperactivity subscale of the ASRS v1.1), stable treatment for at least 30 days at time of inclusion, sufficient German skills, and consent to participation. Exclusion criteria are: Diagnosis of any other severe psychiatric disorder and plans to change treatment in the upcoming three months. Patients will be randomized and allocated to either an intervention group, receiving access to attexis in addition to TAU, or a control group, receiving access to TAU only. Primary endpoint will be self-rated ADHD symptomatology, assessed via the ASRS v1.1, with three months post-allocation being the primary time point for assessment of effectiveness. Six months post allocation will be used as a timepoint for follow-up assessment of endpoints. Secondary endpoints will be depressive symptoms, self-esteem, work and social functioning, and health-related quality of life.

NCT ID: NCT06212895 Active, not recruiting - Physical Activity Clinical Trials

Expectations of Patients Regarding Exercise in an Outpatient Clinic

Start date: December 1, 2023
Phase:
Study type: Observational

Exercise and physical activity are recommended in many clinical guidelines in orthopdeci diseases. Costs, time, doctor-patient-communication and the type of prescription are possible limitations of prescribing exercise as a therapy. It is essential to know the expactiations and attitude of the patients for an accurate, patient-centered, prescription. This trial aims to reveal patients point of view and attitude.

NCT ID: NCT06169982 Active, not recruiting - Clinical trials for Diabetes Mellitus, Type 2

A Multiple Dose Study of LY3209590 in Participants With Type 2 Diabetes

Start date: December 7, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to measure the activity and insulin time action of LY3209590 at steady state in participants with type 2 diabetes mellitus. The total study duration is approximately 182 days.

NCT ID: NCT06168682 Active, not recruiting - Obesity Clinical Trials

Nasal CPAP - The Treatment IMpact on Oxygenation in High-risk Patients During Deep Sedation for Endoscopy

NAPTIME
Start date: November 1, 2023
Phase: N/A
Study type: Interventional

Deep sedation during gastrointestinal endoscopy in patients with cardiopulmonary risk factors such as respective co-morbidities or also morbid obesity is challenging. Those high-risk patients are at risk of upper airway obstruction and hypoxemia. Nasal continuous positive airway pressure may help to decrease the incidence of peri-interventional hypoxemia. However, data on nasal continuous positive airway pressure in high-risk patients having gastrointestinal endoscopy are scarce; only one randomized trial on gastroscopy in obese patients is available (Kang et al. J Anesth 2021). In a very high-risk group, namely patients assessed for heart or lung transplantation in our hospital, the risk was especially high (unpublished data). Aim of this trial is the effect of nasal continuous positive airway pressure - compared to nasal oxygen insufflation - on the incidence of hypoxemia in high-risk patients having gastrointestinal endoscopy in deep sedation. The investigators hypothesize that nasal continuous positive airway pressure - compared to nasal oxygen insufflation - reduces the incidence of hypoxemia in high-risk patients having gastrointestinal endoscopy in deep sedation.

NCT ID: NCT06155656 Active, not recruiting - Clinical trials for Postprandial Metabolic Events

Effects of Pea Proteins With Different Degrees of Processing on Postprandial Metabolism in Healthy Adults

Start date: January 22, 2024
Phase: N/A
Study type: Interventional

The aim of this study is to investigate the postprandial metabolic responses to plant-based protein ingredients of different degrees of processing (pea protein concentrate, isolate, and extrudate) and in comparison to whey protein in healthy adults. Therefore, young healthy subjects consume 4 test meals with 25 g of protein from pea protein concentrate, pea protein isolate, pea protein extrudate or whey protein in a randomized order. In a postprandial period of 6 hours, parameters of protein and glucose metabolism (i.a. plasma amino acids), gastric emptying and hunger/satiety are analysed. It is assumed that the plasma amino acid profile after plant protein ingestion differs depending on processing level of the protein ingredients and in comparison to whey protein.

NCT ID: NCT06155136 Active, not recruiting - Clinical trials for Pancreatic Cancer Metastatic

RWE on Patients With mPDAC Long-term Survival After Treatment With Liposomal Irinotecan

NALLONG
Start date: October 6, 2023
Phase:
Study type: Observational

The objective is to describe mPDAC patients still alive one year after the first cycle of nal-IRI

NCT ID: NCT06153966 Active, not recruiting - Prion Disease Clinical Trials

PrProfile: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION717.

Start date: January 4, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of intrathecal (IT) delivery of ION717.